
    
      A 48 week, Phase II, open-label, 2-cohort, multicenter study to evaluate the
      pharmacokinetics, safety, tolerability and antiviral activity of GW433908 and GW433908/RTV
      when administered to HIV-1 infected protease inhibitor (PI) naive and PI-experienced
      pediatric subjects aged 4 weeks to <2 years.
    
  